Key result
High normotension linked to higher future MetS risk but not non-fatal CVD.
Why the study?
It was unclear whether increased blood pressure within the normotensive range remains associated with MetS and cardiovascular disease.
Does high normotension increase the risk of developing metabolic syndrome and non-fatal cardiovascular events?
Cohort (n=9,133)
Does high normotension increase the risk of developing metabolic syndrome and non-fatal cardiovascular events?
High normotension is associated with an increased risk of developing metabolic syndrome, but not non-fatal cardiovascular events, over a 4-year period.
High normotension may warrant metabolic monitoring; observational data leaves open any role in nonfatal CVD events.
Introduction: Due to the blood pressure was one of the diagnosis criteria in MetS, blood pressure was increased with aging. Whether the increased blood pressure in normotensive range is still associated with MetS and more important, cardiovascular disease, we conducted a 4-year longitudinal observation study to elucidate these association. Methods: a total 9,133 subjects were qualied for analysis. We further grouped these subjects into SBP1 to SBP3 and DBP1 and DBP3. SBP1 was SPB < 99 mmHg, SBP2 was SPB >100, < 109 mmHg, SBP3 was SPB >110, < 119 mmHg. DBP1 was DPB < 59 mmHg, DBP2 was DPB >60, < 69 mmHg, DBP3 was DPB >70, < 79 mmHg. Results: After 4 years of follow-up, SBP3 group still had higher risk of developing future MetS but not future non-fatal cardiovascular diseases. However, SBP3 group in female fail to show signicant in future MetS. In addition, both SPB3 group and DPB3 group fail to show signicant in developing future non-fatal cardiovascular diseases.Kaplan-Meier estimates showed both SPB and DBP groups showed signicant difference in developing future MetS but not in developing future non-fatal cardiovascular diseases. Conclusion: In conclusion, high normotensive bloop pressure is still a risk for having MetS in the future but not non-fatal cardiovascular diseases. DBP looks more sensitive than SBP in the future events development in the elderly.
No takes yet. Share an insight, caveat, or question.
Hsieh et al. (2021) conducted a cohort in Normotension (n=9,133). High normotension (SBP 110-119 mmHg or DBP 70-79 mmHg) vs. Lower normotension was evaluated on Future Metabolic Syndrome (MetS) and non-fatal cardiovascular diseases. High normotension (SBP 110-119 mmHg) was associated with a significantly higher risk of developing future metabolic syndrome over 4 years, but not non-fatal cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: